Abstract 316TiP
Background
Phase 2 studies (NCT02296684 and NCT02641093) with neoadjuvant and adjuvant pembro have demonstrated pathological response (PR) and acceptable safety in pts with high-risk resectable LA HNSCC. The randomized, global, open-label, phase 3 KEYNOTE-689 trial (NCT03765918) will evaluate the efficacy and safety of neoadjuvant pembro and adjuvant pembro plus SOC in pts with previously untreated resectable LA HNSCC.
Trial design
Pts will be randomly assigned 1:1 to two arms. In arm A, pts will receive neoadjuvant pembro (200 mg Q3W, 2 cycles), followed by surgical resection, then SOC plus adjuvant pembro (200 mg Q3W, 15 cycles). In arm B, pts will undergo surgical resection followed by adjuvant SOC without pembro. SOC is radiotherapy (RT) alone (pts at low risk) or RT plus concurrent cisplatin (3 cycles of 100 mg/m2 Q3W) (pts at high risk). RT is standard fractionation at 2 Gy/fraction for 30, 33, or 35 fractions (60 Gy, 66 Gy, or 70 Gy) for pts at low risk or high risk or with gross residual disease, respectively. Randomization will be stratified by primary tumor site (oropharynx/oral cavity vs larynx vs hypopharynx), tumor stage (III vs IVA), and HPV p16 status (oropharynx p16–positive vs oropharynx p16–negative or larynx/hypopharynx/oral cavity). Eligible pts are adults with newly diagnosed, resectable, nonmetastatic stage III/IVA HNSCC (AJCC Cancer Staging Manual, 8th edition), evaluable tumor burden, and ECOG PS 0 or 1 who are eligible for primary surgery. Treatment will continue until disease progression, unacceptable toxicity, or decision to withdraw in both arms. Co-primary end points are major PR (≤10% invasive SCC within resected primary tumor and sampled regional lymph nodes per blinded central pathology) and event-free survival. Secondary end points include overall survival, pathological complete response, quality of life, and safety. The first radiologic imaging in arm A will occur after 2 cycles of pembro and before surgery. Postoperative imaging will occur in both arms 12 weeks after SOC, then every 3 months until year 3 and every 6 months thereafter. Recruitment is ongoing; estimated enrollment is ∼700 pts.
Clinical trial identification
NCT03765918.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
E. Cohen: Advisory / Consultancy: Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Incyte; MSD; Merck. R. Uppaluri: Advisory / Consultancy, Research grant / Funding (self): Merck. N. Lee: Advisory / Consultancy: Merck, Merck Serono, Pfizer, Sanofi; Spouse / Financial dependant, Spouse Stockholder: AstraZeneca. W. Westra: Advisory / Consultancy, Travel / Accommodation / Expenses: Merck. R. Haddad: Advisory / Consultancy: Celgene, Merck, Eisai, Bristol-Myers Squibb, AstraZeneca, Pfizer, Loxo, Genentech, Immunomic Therapeutics; Research grant / Funding (institution): Boehringer Ingelheim, Merck, Bristol-Myers Squibb, Celgene, AstraZeneca, VentiRx, Genentech, Pfizer, Kura. C. Le Tourneau: Honoraria (self), Advisory / Consultancy: Merck Serono, Bristol-Myers Squibb, MSD, Amgen, Novartis, Nanobiotix; Travel / Accommodation / Expenses: Bristol-Myers Squibb, Amgen, MSD, Merck Serono. R. Chernock: Advisory / Consultancy: Merck, Roche. Y. Tao: Research grant / Funding (institution): Debiopharma, MSD, Pfizer; Travel / Accommodation / Expenses: MSD, Merck Serono. I. Brana: Advisory / Consultancy: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Bristol-Myers Squibb, AstraZeneca, Merck Serono; Research grant / Funding (self): AstraZeneca, Bristol-Myers Squibb, Celgene, Gliknik, GlaxoSmithKline, Janssen Oncology, Kura, Merck Sharp & Dohme, Novartis, Orion Pharma GmbH, Pfizer; Travel / Accommodation / Expenses: AstraZeneca Spain, Merck Serono. J.Y. Ge: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. R. Swaby: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. B. Bidadi: Full / Part-time employment: Merck. D. Adkins: Advisory / Consultancy: Pfizer, Eli Lilly, Merck, Celgene; Travel / Accommodation / Expenses: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract